Search Results

Senhwa Biosciences, Inc. announced that Taiwan Food and Drug Administration has approved its Phase II IND application of Silmitasertib to treat patients with community-acquired pneumonia caused by viral infection.

Senhwa Biosciences, Inc. announced that their first patient has been successfully dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19.

Senhwa Biosciences, Inc. announced that U.S. Food and Drug Administration has approved its Phase II IND application of Silmitasertib to treat patients with community-acquired pneumonia caused by viral infection.

Senhwa Biosciences, Inc. (TPEx: 6492) announced today that it has submitted an Investigational New Drug (IND) application to U.S. Food and Drug Administration to evaluate its investigational drug, Silmitasertib(CX-4945), for treating patients with community-acquired pneumonia (CAP) caused by viral infection.

Senhwa Biosciences, Inc. announced today that Taiwan FDA has approved its Phase II IND application of Silmitasertib(CX-4945) to treat hospitalized patients with moderate to severe COVID-1.

Senhwa Biosciences, Inc. announced that their first in class new drug Pidnarulex (CX-5461) has been successfully selected to the anticancer pipeline of NIH-sponsored NExT Program (NCI Experimental Therapeutics Program), which will foster the exploration of its therapeutic potential in unmet medical needs and advancement to market.

Senhwa Biosciences, Inc. announced today that their first patient has been successfully dosed, in a phase I clinical study evaluating the combined treatment with Senhwa’s Pidnarulex.

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that it has received written approval from the Human Research Ethics Committee (HREC), Australia to begin a Phase I study evaluating Senhwa’s Pidnarulex, the 2019 PCF-Pfizer Global Challenge Awards winner will be used in combination with Pfizer’s PARP inhibitor, Talazoparib.

Aadi Bioscience expects that pipeline adjustments and the workforce reduction will extend its cash runway into at least the second half of 2026.